These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16287475)

  • 1. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Lau DH; Thompson CS; Morgan RJ; Mumtaz FH; Mikhailidis DP
    BJU Int; 2005 Dec; 96(9):1424. PubMed ID: 16287475
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F; Longhurst PA; White MD
    BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epimedium brevicornum Maxim extract relaxes rabbit corpus cavernosum through multitargets on nitric oxide/cyclic guanosine monophosphate signaling pathway.
    Chiu JH; Chen KK; Chien TM; Chiou WF; Chen CC; Wang JY; Lui WY; Wu CW
    Int J Impot Res; 2006; 18(4):335-42. PubMed ID: 16395327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel compound JPM8: in vivo penile activity promotion in rats, effect on the relaxation and cGMP/cAMP accumulation in isolated rabbit corpora cavernosa.
    El-Thaher TS; Khatib S; Saleem M; Shnoudeh A; Badwan AA
    Int J Impot Res; 2002 Dec; 14(6):453-61. PubMed ID: 12494277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase-5 inhibition synergizes rho-kinase antagonism and enhances erectile response in male hypertensive rats.
    Wilkes N; White S; Stein P; Bernie J; Rajasekaran M
    Int J Impot Res; 2004 Apr; 16(2):187-94. PubMed ID: 15073608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor.
    Mochida H; Takagi M; Inoue H; Noto T; Yano K; Fujishige K; Sasaki T; Yuasa K; Kotera J; Omori K; Kikkawa K
    Eur J Pharmacol; 2002 Dec; 456(1-3):91-8. PubMed ID: 12450574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.
    Doh H; Shin CY; Son M; Ko JI; Yoo M; Kim SH; Kim WB
    Arch Pharm Res; 2002 Dec; 25(6):873-8. PubMed ID: 12510841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide regulation of penile erection: biology and therapeutic implications.
    Burnett AL
    J Androl; 2002; 23(5):S20-6. PubMed ID: 12236169
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent insights into androgen action on the anatomical and physiological substrate of penile erection.
    Gooren LJ; Saad F
    Asian J Androl; 2006 Jan; 8(1):3-9. PubMed ID: 16372114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 11. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
    Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
    Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FR226807: a potent and selective phosphodiesterase type 5 inhibitor.
    Hosogai N; Hamada K; Tomita M; Nagashima A; Takahashi T; Sekizawa T; Mizutani T; Urano Y; Kuroda A; Sawada K; Ozaki T; Seki J; Goto T
    Eur J Pharmacol; 2001 Oct; 428(2):295-302. PubMed ID: 11675048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.
    Seftel AD
    J Urol; 2005 Sep; 174(3):1043. PubMed ID: 16094045
    [No Abstract]   [Full Text] [Related]  

  • 15. [7 years PDE-5 inhibitor for therapy of erection disorders].
    Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
    [No Abstract]   [Full Text] [Related]  

  • 16. Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.
    Aversa A; Pili M; Fabbri A; Spera E; Spera G
    J Endocrinol Invest; 2004 Feb; 27(2):192-206. PubMed ID: 15129818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.
    Zhang XH; Morelli A; Luconi M; Vignozzi L; Filippi S; Marini M; Vannelli GB; Mancina R; Forti G; Maggi M
    Eur Urol; 2005 Mar; 47(3):409-16; discussion 416. PubMed ID: 15716209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
    Lincoln TM
    Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859.
    Qiu Y; Bhattacharjee S; Kraft P; John TM; Craig E; Haynes-Johnson D; Guan J; Jiang W; Macielag M; Sui Z; Clancy J; Lundeen S
    Eur J Pharmacol; 2003 Jul; 472(1-2):73-80. PubMed ID: 12860475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.